CA2848369A1 - Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene - Google Patents

Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene Download PDF

Info

Publication number
CA2848369A1
CA2848369A1 CA 2848369 CA2848369A CA2848369A1 CA 2848369 A1 CA2848369 A1 CA 2848369A1 CA 2848369 CA2848369 CA 2848369 CA 2848369 A CA2848369 A CA 2848369A CA 2848369 A1 CA2848369 A1 CA 2848369A1
Authority
CA
Canada
Prior art keywords
ret
kif5b
gene
fusion
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2848369
Other languages
English (en)
French (fr)
Inventor
Takashi Kohno
Koji Tsuta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Japan
LSIP LLC
Original Assignee
National Cancer Center Japan
LSIP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center Japan, LSIP LLC filed Critical National Cancer Center Japan
Publication of CA2848369A1 publication Critical patent/CA2848369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
CA 2848369 2011-08-04 2012-08-03 Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene Abandoned CA2848369A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-171256 2011-08-04
JP2011171256 2011-08-04
PCT/JP2012/069799 WO2013018882A1 (ja) 2011-08-04 2012-08-03 Ｋｉｆ５ｂ遺伝子とｒｅｔ遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法

Publications (1)

Publication Number Publication Date
CA2848369A1 true CA2848369A1 (en) 2013-02-07

Family

ID=47629396

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2848369 Abandoned CA2848369A1 (en) 2011-08-04 2012-08-03 Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene

Country Status (8)

Country Link
US (1) US9216172B2 (OSRAM)
EP (1) EP2740742B1 (OSRAM)
JP (1) JP6032616B2 (OSRAM)
KR (1) KR20140047138A (OSRAM)
CN (1) CN103764676A (OSRAM)
CA (1) CA2848369A1 (OSRAM)
IN (1) IN2014DN01605A (OSRAM)
WO (1) WO2013018882A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12239648B2 (en) 2011-08-23 2025-03-04 Foundation Medicine, Inc. KIF5B-RET fusion molecules and uses thereof

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
JP5780527B2 (ja) 2010-09-02 2015-09-16 学校法人 久留米大学 単分子ｄｎａから形成される環状ｄｎａの作成方法
US9416358B2 (en) 2011-08-31 2016-08-16 Kurume University Method for exclusive selection of circularized DNA from monomolecular DNA in circularizing DNA molecules
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
SG11201502211QA (en) 2012-09-25 2015-05-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
KR101874501B1 (ko) * 2013-03-15 2018-07-05 익스프레션 패톨로지, 인크. 암 요법을 지시하는 srm 검정
WO2015025866A1 (ja) 2013-08-20 2015-02-26 独立行政法人国立がん研究センター 肺がんで見出された新規融合遺伝子
US20160053301A1 (en) 2014-08-22 2016-02-25 Clearfork Bioscience, Inc. Methods for quantitative genetic analysis of cell free dna
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
RS61485B1 (sr) 2015-07-16 2021-03-31 Array Biopharma Inc Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze
IL302209B2 (en) 2015-11-02 2024-06-01 Blueprint Medicines Corp Inhibitors of ret
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018102455A1 (en) 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110891573A (zh) 2017-05-15 2020-03-17 缆图药品公司 Ret抑制剂和mtorc1抑制剂的组合及其用于治疗由异常ret活性介导的癌症的用途
SG11202001212SA (en) * 2017-08-21 2020-03-30 Taiho Pharmaceutical Co Ltd Fusion protein of dctn1 protein with ret protein
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
PT3773589T (pt) 2018-04-03 2024-02-06 Blueprint Medicines Corp Inibidor de ret para utilização no tratamento de cancro com alteração de ret
WO2020033838A2 (en) 2018-08-10 2020-02-13 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
CN111154872A (zh) * 2019-12-31 2020-05-15 浙江大学 用于检测肺癌驱动性基因突变的探针及试剂盒
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CN111909987A (zh) * 2020-07-31 2020-11-10 浙江科途医学科技有限公司 用于kif5b-ret融合基因检测的试剂组合物、试剂盒及检测系统
CN113637709B (zh) * 2021-08-14 2023-01-17 中国农业科学院兰州兽医研究所 Kif5b基因作为靶点在抑制口蹄疫病毒复制中的应用
JP2023177142A (ja) * 2022-06-01 2023-12-13 国立研究開発法人国立がん研究センター Ｒｅｔキナーゼ阻害剤によるがん治療の有効性を判定する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598052B2 (en) * 2005-10-11 2009-10-06 The Regents Of The University Of Michigan Expression profile of thyroid cancer
JPWO2007049624A1 (ja) * 2005-10-24 2009-04-30 武田薬品工業株式会社 癌の予防・治療剤
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
KR20090094815A (ko) * 2006-11-09 2009-09-08 애보트 게엠베하 운트 콤파니 카게 티로신 키나아제 억제제의 경구 투여를 위한 약제 투여형
WO2010000012A1 (en) * 2008-07-03 2010-01-07 The University Of Sydney Method for preventing transport of a neurotropic virus
US20130137111A1 (en) * 2010-07-26 2013-05-30 Astellas Pharma Inc. Detection method of novel ret fusion
JP2014005206A (ja) 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12239648B2 (en) 2011-08-23 2025-03-04 Foundation Medicine, Inc. KIF5B-RET fusion molecules and uses thereof

Also Published As

Publication number Publication date
JP6032616B2 (ja) 2016-11-30
EP2740742A4 (en) 2015-06-17
JPWO2013018882A1 (ja) 2015-03-05
KR20140047138A (ko) 2014-04-21
US20140221404A1 (en) 2014-08-07
IN2014DN01605A (OSRAM) 2015-05-15
WO2013018882A1 (ja) 2013-02-07
EP2740742B1 (en) 2018-03-14
CN103764676A (zh) 2014-04-30
EP2740742A1 (en) 2014-06-11
US9216172B2 (en) 2015-12-22

Similar Documents

Publication Publication Date Title
US9216172B2 (en) Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
JP6493681B2 (ja) 肺がんで見出された新規融合遺伝子
JP6223451B2 (ja) がんの診断及び治療方法
EP2878672A1 (en) Fusion gene of cep55 gene and ret gene
EP2871236A1 (en) Fgfr2 fusion gene
JP2010505446A (ja) Ｅｒｇ遺伝子発現における前立腺癌特異的変化ならびにそれらの変化に基づく検出および治療方法
WO2013141266A1 (ja) 新規ｒｅｔ融合体の検出法
JPWO2015064621A1 (ja) 新規融合体及びその検出法
JPWO2017122815A1 (ja) 新規融合体及びその検出法
WO2015093557A1 (ja) 胃がんの責任因子としての新規融合遺伝子
JP6519927B2 (ja) 癌の診断、阻害剤のスクリーニングにおけるｒｈｏａの使用
WO2022244807A1 (ja) Ｌｔｋ融合遺伝子
JPWO2017122816A1 (ja) 新規融合体及びその検出法
JP6806440B2 (ja) 新規融合体及びその検出法
JP2017135985A (ja) Ｂ前駆細胞性急性リンパ芽球性白血病新規キメラ遺伝子
WO2008075713A1 (ja) 癌診断用マーカーならびに治療の標的分子

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170803